CollPlant Biotechnologies Ltd. (CLGN)

NCM – Real Time Price. Currency in USD

0.41

+0.01 (2.97%)

At close: May 12, 2026, 4:00 PM EDT

0.40

-0.00 (-0.67%)

After-hours: May 12, 2026, 7:16 PM EDT

13.04.2026

CollPlant Issues Letter to Shareholders

REHOVOT, Israel, April 13, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), is pleased to issue the following letter from its Chief Executive Officer, Yehiel Tal. Dear Shareholders, This morning, we announced the termination of our development agreement with AbbVie.

26.03.2026

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

REHOVOT, Israel, March 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived rhCollagen for tissue regeneration and medical aesthetics, today announced its 2025 financial results and provided a corporate update. "Over the past year, we have made meaningful progress across all fronts-from advancing our collaborative programs to building momentum in our proprietary pipeline and commercial product portfolio.

24.03.2026

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

REHOVOT, Israel, March 24, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that on March 23, 2026, the Company received a written notice (the "Notice") from the Nasdaq Stock Market LLC indicating that the Company was not in compliance with Nasdaq Listing Rule 5550(a)(2), as the Company's closing bid price for its ordinary shares, or Ordinary Shares, was below $1.00 per share for the last 30 consecutive business days. Pursuant to Nasdaq Listing Rule 5810(c)(3)(A), the Company has been granted a 180-calendar day compliance period, or until September 21, 2026, to regain compliance with the minimum bid price requirement.

18.03.2026

CollPlant Biotechnologies Launches Redesigned Corporate Website

REHOVOT, Israel, March 18, 2026 /PRNewswire/ -- CollPlant (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary plant-derived recombinant human collagen (rhCollagen), today announced the launch of its redesigned corporate website at www.collplant.com . The new website provides expanded information regarding the Company's technology platform, product pipeline, strategic collaborations and corporate governance, and is intended to enhance transparency and accessibility for investors, partners, and other stakeholders.

11.03.2026

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

REHOVOT, Israel, March 11, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetics medicine company developing innovative technologies and products based on its non-animal-derived collagen for medical aesthetics and tissue regeneration, today announced that it will report financial results for the full year of 2025 on Thursday, March 26, 2026, before the opening of the U.S. financial markets. About CollPlant CollPlant is a regenerative and aesthetic medicine company ushering in a new era of medical solutions with a focus on medical aesthetics and 3D bioprinting of tissues and organs.

26.02.2026

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

Intellectual Property Rights Secured in One of the Largest Target Markets for CollPlant's Product Candidate REHOVOT, Israel, Feb. 26, 2026 /PRNewswire/ -- CollPlant Biotechnologies (Nasdaq: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced that the Korean Patent Office has allowed a patent application covering key aspects of the Company's photocurable dermal filler technology currently under development for the aesthetic market. The allowed patent application covers a polymerizable solution and its use in tissue augmentation.

23.02.2026

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

BioFlex Enables Rapid Formulation of Tunable rhCollagen Bioinks with Enhanced Tissue-Mimetic Performance BioFlex Expands CollPlant's Animal-Free Bioink Platform for Biopharma companies and Academic institutions Seeking Superior Biofunctionality and Reproducibility REHOVOT, Israel, Feb. 23, 2026 /PRNewswire/ -- CollPlant (NASDAQ: CLGN), a regenerative and aesthetic medicine company developing innovative technologies and products based on its proprietary recombinant human collagen (rhCollagen) platform, today announced the launch of BioFlex, a ready-to-print rhCollagen-based kit designed for Digital Light Processing (DLP) 3D bioprinting applications. BioFlex is engineered to support the biofabrication of advanced tissue models for drug discovery, as well as the development of engineered tissues and transplantable organs.

Videos

No Data

There is no data to display

Press releases

13.04.2026

CollPlant Issues Letter to Shareholders

26.03.2026

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

24.03.2026

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

18.03.2026

CollPlant Biotechnologies Ltd. (CLGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CollPlant Biotechnologies Ltd. (CLGN)

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

Videos

No Data

Press releases

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

Videos

No Data

Press releases

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

Search stocks

CollPlant Biotechnologies Ltd. (CLGN)

Get all premium features to the best stock analysis tool

Finranks

Company

Contact us

Follow us

CollPlant Biotechnologies Ltd. (CLGN)

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

Videos

No Data

Press releases

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website

COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR FULL YEAR 2025 FINANCIAL RESULTS

CollPlant Biotechnologies Announces Korean Patent Allowance Secured for its Photocurable Dermal Filler

CollPlant Elevates rhCollagen 3D Bioprinting Portfolio with Launch of Ready-to-Print BioFlex

Videos

No Data

Press releases

CollPlant Issues Letter to Shareholders

COLLPLANT BIOTECHNOLOGIES REPORTS 2025 FINANCIAL RESULTS AND PROVIDES CORPORATE UPDATE

CollPlant Biotechnologies Receives Nasdaq Notification Regarding Minimum Bid Requirement

CollPlant Biotechnologies Launches Redesigned Corporate Website